SeekingAlpha · Aug 8, 2026
Merck KGaA (MKKGY) Q2 2026 Earnings Call Transcript
Merck KGaA (MKKGY) Q2 2026 Earnings Call August 6, 2026 8:00 AM EDTCompany ParticipantsFlorian Schraeder - Head of Investor RelationsKai Beckmann - CEO...
OTC · MKKGY
Merck KGaA
Healthcare · Drug Manufacturers - Specialty & Generic
$30.49
Down-$0.37 (-1.20%)
Updated Sep 11, 2026, 3:12 AM
SID Score
7.1/10
Composite research score
Smart Money
46/100
Neutral
- Market cap
- 61.14B
- P/E ratio
- 17.39
- Dividend yield
- 1.64%
- 52-week range
- $23.73 – $34.19
- Volume
- 40.26K
- Avg. volume
- 155.75K
Price performance
MKKGY price history
1M range · 18 trading sessions · Daily adjusted prices
MKKGY closed at $31.18 after 18 trading sessions, down 3.41% for the selected period.
- Last close
- $31.18
- Period change
- -3.41%
- Period low
- $31.18
- Period high
- $32.73
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 8, 2026 | $31.58 | $31.6075 | $31.18 | $31.18 | 40.26K |
| Sep 4, 2026 | $31.48 | $31.83 | $31.47 | $31.51 | 29.51K |
| Sep 3, 2026 | $32.5535 | $32.57 | $31.8295 | $32.10 | 37.02K |
| Sep 2, 2026 | $32.466 | $32.474 | $32.30 | $32.38 | 45.12K |
| Sep 1, 2026 | $32.96 | $32.96 | $32.26 | $32.33 | 24.67K |
| Aug 31, 2026 | $32.3075 | $32.37 | $32.14 | $32.26 | 43.53K |
| Aug 28, 2026 | $32.54 | $32.68 | $32.38 | $32.45 | 25.64K |
| Aug 27, 2026 | $32.22 | $32.83 | $32.16 | $32.73 | 34.61K |
| Aug 26, 2026 | $32.35 | $32.62 | $32.35 | $32.46 | 42.9K |
| Aug 25, 2026 | $32.24 | $32.6915 | $32.24 | $32.55 | 31.06K |
| Aug 24, 2026 | $32.27 | $32.49 | $32.14 | $32.36 | 63.15K |
| Aug 21, 2026 | $31.99 | $32.32 | $31.91 | $32.24 | 26.54K |
| Aug 20, 2026 | $31.94 | $32.30 | $31.936 | $32.05 | 32.03K |
| Aug 19, 2026 | $32.37 | $32.69 | $32.25 | $32.45 | 28.93K |
| Aug 18, 2026 | $31.64 | $32.08 | $31.54 | $31.674 | 61.74K |
| Aug 17, 2026 | $31.58 | $31.64 | $31.4725 | $31.555 | 204.79K |
| Aug 14, 2026 | $31.80 | $31.80 | $31.3415 | $31.58 | 65.8K |
| Aug 13, 2026 | $32.407 | $32.41 | $32.17 | $32.28 | 24.81K |
Latest MKKGY news
The latest Smart Investors Daily articles mentioning MKKGY.
Stock researchCompany · Overview
MKKGY research
Overview
Company profile and research snapshot.
Company profile
MERCK KGAA SPNS/ADR
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $53.96
- Implied upside
- —
- Analysts
- 10
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 12, 2026 | DAY BY DAY | Buy | — |
| Jul 12, 2026 | LANDESBANK BADEN-WUERTTEMBERG | Buy | — |
| Jul 8, 2026 | ROTHSCHILD & CO REDBURN | Buy | — |
| Jun 25, 2026 | ODDO BHF | Buy | — |
| Jun 25, 2026 | EQUITA SIM | Hold | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 7, 2026
Merck KGaA 2026 Q2 - Results - Earnings Call Presentation
2026-08-07. The following slide deck was published by Merck KGaA in conjunction with their 2026 Q2 earnings call.
Yahoo · Jun 26, 2026
Merck KGaA (MKKGY) Soars 5.3%: Is Further Upside Left in the Stock?
Merck KGaA (MKKGY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Yahoo · Jun 26, 2026
FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services
Replimune’s application is the latest example of changing attitudes at the FDA. Elsewhere, Revolution Medicines outlined more RAS-blocking data and a Definium stock offering brought in $800 million.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
